Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade + Temozolomide + Radiation for Newly Diagnosed GBM
NCT00998010Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in glioblastoma multiforme (GBM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00998010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998010.